Search Results

1 - 10 of 47 items :

  • T regulatory cell x
  • Basic Medical Science x
  • Clinical Medicine x
  • Clinical Medicine, other x
Clear All

. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008;133:775 - 787. 26. Numasaki M, Fukushi J-I, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H, Lotze PJ. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003;101:2620-2627. 27. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010;127:759-767. 28. Li MO, Sanjabi S, Flavell R. Transforming growth factor-β controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity

References 1. Tsao BP. Update on human systemic lupus erythematosus genetics. Curr Opin Rheumatol. 2004; 16:513-21. 10.1097/01.bor.0000132648.62680.81 2. Zhang H, Yang P, Zhou H, Meng Q, Huang X: Involvement of Foxp3-expressing CD4+ CD25+ regulatory T cells in the development of tolerance induced by transforming growth factor-beta2-treated antigen-presenting cells. Immunology. 2008; 124: 304-14. 3. Namba K, Kitaichi N, Nishida T, Taylor AW. Induction of regulatory T cells by the immunomodulating cytokines alpha-melanocyte-stimulating hormone and transforming

-483. 20. Chung Y., S. H. Chang, G. J. Martinez et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. – Immunity, 30, 2009, № 4, 576-587. 21. Chen W. J., W. Jin, N. Hardegen et al. Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3. – J Exp Med, 198, 2003, № 12, 1875-1886. 22. Zheng S. G., J. Wang, P. Wang et al. IL-2 Is Essential for TGF-β to Convert Naive CD4+CD25− Cells to CD25+Foxp3+ Regulatory T Cells and for Expansion of These Cells. – J Immunol, 178

:837-845. 10.1095/biolreprod.103.021147 21. Bendall SC, Stewart MH, Menendez P, George D, Vijayaragavan K, Werbowetski-Ogilvie T, et al. IGF and FGF cooperatively establish the regulatory stem cell niche of pluripotent human cells in vitro. Nature. 2007; 448:1015-21. 22. Lei T, Jacob S, Ajil-Zaraa I, Dubuisson JB, Irion O, Jaconi M, Feki A. Xeno-free derivation and culture of human embryonic stem cells: current status, problems and challenges. Cell Res. 2007; 17:682-8. 10.1038/cr.2007.61 23. Swistowski A, Peng J, Han Y, Swistowska AM, Rao MS, Zeng X. Xeno-free defined

References 1. Calderwood SK, Mambula SS, Gray PJ Jr. Extracellular heat shock proteins in cell signaling and immunity. Ann NY Acad Sci. 2007; 1113:28-39. 2. V, Hauet-Broere F, Berlo S, Paul L, van der Zee R, de Kleer I,et al. Stress proteins as inducers and targets of regulatory T cells in arthritis. Int Rev Immunol. 2005; 24:181-97. 10.1080/08830180590934958 3. Pockley AG, Muthana M, Calderwood SK. The dual immunoregulatory roles of stress proteins. Trends Biochem Sci. 2008; 33:71-9. 4. Gupta RS, Ramachandra NB, Bowes T, Singh B. Unusual cellular disposition of

Genet. 1995; 11:101-5. 10.1016/S0168-9525(00)89010-1 5. Hall PA, Meek D, Lane DP. p53-integrating the complexity. J Pathol. 1996; 180:1-5. 10.1002/(SICI)1096-9896(199609)180:1<1::AID-PATH712>3.0.CO;2-U 6. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994; 9:1799-805. 7. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993; 366:704-7. 8. Mork J, Lie AK

.Update Cancer Ther 2007; 2: 61-65. 14. Piconese S, Valzasina B, Colombo MP. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 2008; 205: 825-39. 15. Marin-Acevedo JA, Soyano AE, Dholaria B, et al. Cancer immunotherapy beyond immune checkpoint inhibitors. J Hematol Oncol 2018; 11: 8. 16. Amedei A, Benagiano M, della Bella C, et al. Novel immuno-therapeutic strategies of gastric cancer treatment. J Biomed Biotechnol 2011; 2011: 437348. 17. Yoshikawa T, Tsuburaya A, Kobayashi O et al. Plasma concentrations of VEGF and bFGF in

References 1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71-96. 2. Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, Fujii H. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer. 2008; 122:2286-93. 3. Panani AD. Cytogenetic and molecular aspects of gastric cancer: clinical implications. Cancer Lett. 2008; 266:99-115. 4. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40/ CD154 interactions

-206. 12. Impey S, McCorkle SR, Cha-Molstad H, Dwyer JM, Yochum GS. Defining the CREB regulon: a genomewide analysis of transcription factor regulatory regions. Cell. 2004; 119:1041-54. 13. Maiese K, Chong ZZ, Shang YC. OutFOXOing disease and disability: The therapeutic potential of targeting FoxO proteins. Trends Mol Med. 2008; 14:219-27. 14. Guo S, Rena G, Cichy S, He X, Cohen P, Unterman T. Phosphorylation of serine 256 by protein kinase B disrupts transactivation by FKHR and mediates effects of insulin on insulin-like growth factor-binding protein-1 promoter activity

, Feokistov I, Denenberg A, et al. The A2A receptor mediates an endogenous regulatory pathway of cytokine expression in THP-1 cells. J Leukoc Biol. 2002; 72: 1027-37. 35. Minguest S, Huber M, Rosenkranz L, Schamel WA, Reth M, Brummer T. Adenosine and cAMP are potent inhibitors of the NF-κB pathway downstream of immunoreceptors. Eur J Immunol. 2005; 35:31-41. 10.1002/eji.200425524 36. Lukashev D, Ohta A, Apasov S, Chen JF, Sitkovsky M. Cutting edge: physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor in vivo. J Immunol